{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:45Z","timestamp":1790383845507,"version":"4.1.0"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.12788\/fp.0571","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:42:15Z","timestamp":1749584535000},"source":"Crossref","is-referenced-by-count":2,"title":["Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?"],"prefix":"10.12788","volume":"42","author":[{"given":"Danna","family":"Hanks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","published-online":{"date-parts":[[2025,6]]},"container-title":["Federal Practitioner"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/0625FED%20Pharmacology.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:42:15Z","timestamp":1749584535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/fedprac\/article\/272592\/pharmacy\/are-oritavancin-and-dalbavancin-more-cost-effective-outpatient-parenteral-antimicrobial-therapy-veterans-affairs-medical-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.12788\/fp.0571","relation":{},"subject":[],"published":{"date-parts":[[2025,6]]}}}